Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-002 in Advanced Solid Tumors and Lymphomas
NCT04306224Phase 1Completed
- Sponsor
- ImmuneOncia Therapeutics, Inc.
- Start
- Jun 2020
- Primary completion
- Oct 2022
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of IMC-002 in solid tumor and lymphoma, sponsored by ImmuneOncia Therapeutics, Inc. Primary endpoints: Dose-Limiting Toxicities at 28 days and Adverse Events at 2 years. Started Jun 2020; status: completed.
02
Drugs
IMC-002
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT04306224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04306224.